Travere Therapeutics, Inc. (TVTX)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research
View more

Current Price

as of Mar 14, 2025

$19.73

P/E Ratio

N/A

Market Cap

$1.75B

Mar 21, 2024Apr 25, 2024May 30, 2024Jul 3, 2024Aug 5, 2024Sep 6, 2024Oct 10, 2024Nov 13, 2024Dec 19, 2024Jan 28, 2025Mar 14, 2025$0.00$10.00$20.00
  • DHCA
Description
Add to research
View more

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Metrics
Add to research
View more

Overview

  • HQSan Diego, CA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerTVTX
  • Price$19.73+3.14%

Trading Information

  • Market cap$1.75B
  • Float98.50%
  • Average Daily Volume (1m)1,695,218
  • Average Daily Volume (3m)1,593,157
  • EPS-$4.08

Company

  • Revenue$233.17M
  • Rev growth (1yr)60.55%
  • Net income-$320.63M
  • Gross margin78.00%
  • EBITDA margin-91.19%
  • EBITDA-$212.63M
  • EV$1.41B
  • EV/Revenue6.03
  • P/EN/A
  • P/S6.68
  • P/B29.21
  • Debt/Equity679.76
Documents
Add to research
View more